Fulgent Genetics financials
$22.08−1.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85.4M | $71.1M | $83.3M | $84.1M | $81.8M | $73.5M | $76.2M | $71.7M | $71.0M | $64.5M | $70.5M | $84.7M |
| Gross profit | $25.7M | $21.5M | $32.6M | $35.5M | $34.4M | $28.3M | $31.8M | $26.8M | $26.5M | $22.1M | $25.2M | $39.8M |
| Gross margin | 30.1% | 30.2% | 39.1% | 42.2% | 42.1% | 38.6% | 41.8% | 37.3% | 37.3% | 34.3% | 35.8% | 47.0% |
| Operating income | -$36.1M | -$34.6M | -$36.2M | -$15.3M | -$29.6M | -$19.8M | -$16.1M | -$17.1M | -$18.9M | -$21.8M | -$151.1M | $214.0K |
| Net income | -$29.5M | -$24.8M | -$23.4M | -$6.6M | -$19.0M | -$11.5M | -$5.9M | -$14.6M | -$8.7M | -$13.5M | -$128.1M | -$13.1M |
| Net margin | −34.6% | −34.9% | −28.1% | −7.9% | −23.2% | −15.7% | −7.7% | −20.4% | −12.3% | −20.9% | −181.8% | −15.5% |
| Diluted EPS | $-1.05 | $-0.80 | $-0.76 | $-0.21 | $-0.62 | $-0.37 | $-0.19 | $-0.48 | $-0.29 | $-0.45 | $-4.30 | $-0.44 |
| EBITDA | -$26.2M | -$28.6M | -$30.1M | -$9.3M | -$13.7M | -$13.9M | -$9.9M | -$11.2M | -$12.8M | -$15.1M | -$30.9M | $6.6M |
| Operating cash flow | -$23.8M | $7.1M | -$78.1M | $11.1M | -$30.2M | -$4.4M | $25.0M | -$15.5M | $4.3M | $7.3M | $14.9M | $10.2M |
| Free cash flow | -$27.6M | $1.9M | -$83.1M | $5.1M | -$37.0M | -$9.1M | $21.2M | -$35.0M | -$8.7M | $3.2M | $11.8M | $5.3M |
| Diluted shares | 28.0M | 30.9M | 31.0M | 30.7M | 30.5M | 30.8M | 30.7M | 30.4M | 30.1M | 29.8M | 29.8M | 30.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.3M | $23.4M | $50.2M | $117.6M | $87.9M | $67.3M |
| Short-term investments | $230.7M | $252.9M | $285.9M | $258.2M | $205.0M | $253.0M |
| Total debt | $482.0K | $482.0K | $476.0K | $476.0K | $476.0K | $476.0K |
| Total assets | $1.09B | $1.16B | $1.21B | $1.21B | $1.20B | $1.21B |
| Total liabilities | $93.2M | $112.2M | $106.8M | $93.8M | $88.2M | $83.0M |
| Shareholders' equity | $996.0M | $1.04B | $1.11B | $1.12B | $1.11B | $1.12B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology